Otida is a technology company.
Otida has raised $340K across 1 funding round.
Otida has raised $340K in total across 1 funding round.
Otida is an Egypt-based HealthTech company providing AI-powered SaaS solutions for chronic disease management, primarily targeting diabetes in hospitals and clinics.[1][2][6] It offers a comprehensive digital platform combining personalized nutrition plans, continuous remote monitoring via wearables, a patient mobile app, AI-driven analytics, and telehealth to reverse Type 2 diabetes and manage Type 1, while expanding to hypertension, obesity, and chronic kidney disease.[1][2][3][6] Serving patients, healthcare providers, and institutions in the Middle East, Otida solves fragmented chronic care by enabling real-time data insights, EHR integration, and multidisciplinary team collaboration, with early funding of $340,000 signaling growth momentum from investors like Flat6Labs and Afropreneurs.[1][5]
Otida was co-founded in Cairo, Egypt, by Ahmed Tawfic Saleh (CEO, CS from AUC, MBA from University of Chicago Booth, prior experience in consulting, business development, tech, and product at instadiet.me) and Ayman Mostafa (COO, BBus from AlexU, background in software development, digital marketing, and startups at egr2atk).[1][2] The idea emerged from addressing diabetes management gaps, building on Saleh's earlier nutrition app instadiet.me, evolving into a full chronic care platform with AI and telemonitoring.[1][5] Early traction included raising $340,000 in 2022 from Afropreneurs, Flat6Labs, LoftyInc, UI Investments, and Jedar Capital, plus operational scaling with Inas Abdelwahed as Head of Medical Operations.[1][2][5]
Otida rides the digital health boom in emerging markets, where diabetes prevalence is surging (e.g., Middle East/North Africa) amid rising smartphone penetration and post-pandemic telehealth demand.[1][2][5] Timing aligns with AI advancements enabling predictive chronic care, countering market forces like healthcare worker shortages and high chronic disease costs through scalable SaaS.[3][6] It influences the ecosystem by pioneering Arabic-localized HealthTech, integrating with local EHRs, and attracting regional VC, potentially accelerating AI adoption in African/Arab startups for preventive care.[1][5]
Otida is positioned for expansion into more chronic conditions and pan-African/MENA markets, leveraging AI enhancements and partnerships with hospitals for subscription revenue growth.[6] Trends like wearable proliferation, regulatory support for digital therapeutics, and VC influx into HealthTech will propel it, evolving from diabetes specialist to full chronic care leader—potentially mirroring global players like Livongo while dominating local gaps.[2][3] Watch for Series A funding and outcome data proving reversal rates to cement its transformative edge in accessible care.
Otida has raised $340K in total across 1 funding round.
Otida's investors include E62 Ventures, Jedar Capital.
Otida has raised $340K across 1 funding round. Most recently, it raised $340K Seed in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $340K Seed | E62 Ventures, Jedar Capital |